Skip to main content
Premium Trial:

Request an Annual Quote

BioMerieux to Incorporate Cepheid s Platform in Molecular Diagnostics

NEW YORK, Jan. 6 (GenomeWeb News) - BioMerieux of Marcy-l'Etoile, France, plans to develop molecular diagnostics systems using Cepheid's platform technologies, Sunnyvale, Calif.-based Cepheid said today.

 

The testing units will combine BioMerieux's NASBA (Nucleic Acid Sequence-Based Amplification) technology and Cepheid's Smart Cycler and GeneXpert platforms.

 

BioMerieux will pay Cepheid a total of $15 million in upfront and milestone payments, including a $2 million option payment received in October 2003. Cepheid will also receive payments from product purchases and royalties. 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.